Aridis Pharmaceuticals (ARDS) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends ARDS vs. SCPS, VAXX, EVLO, CMRA, GNCA, CALA, AMPE, CLVR, EFTR, and PXMDShould you be buying Aridis Pharmaceuticals stock or one of its competitors? The main competitors of Aridis Pharmaceuticals include Scopus BioPharma (SCPS), Vaxxinity (VAXX), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCA), Calithera Biosciences (CALA), Ampio Pharmaceuticals (AMPE), Clever Leaves (CLVR), eFFECTOR Therapeutics (EFTR), and PaxMedica (PXMD). These companies are all part of the "pharmaceutical products" industry. Aridis Pharmaceuticals vs. Scopus BioPharma Vaxxinity Evelo Biosciences Comera Life Sciences Genocea Biosciences Calithera Biosciences Ampio Pharmaceuticals Clever Leaves eFFECTOR Therapeutics PaxMedica Aridis Pharmaceuticals (NASDAQ:ARDS) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, valuation and community ranking. Does the media refer more to ARDS or SCPS? In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score. Company Overall Sentiment Aridis Pharmaceuticals Neutral Scopus BioPharma Neutral Which has more risk & volatility, ARDS or SCPS? Aridis Pharmaceuticals has a beta of 9.82, indicating that its share price is 882% more volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.19, indicating that its share price is 119% less volatile than the S&P 500. Is ARDS or SCPS more profitable? Company Net Margins Return on Equity Return on Assets Aridis PharmaceuticalsN/A N/A N/A Scopus BioPharma N/A N/A N/A Does the MarketBeat Community favor ARDS or SCPS? Aridis Pharmaceuticals received 120 more outperform votes than Scopus BioPharma when rated by MarketBeat users. However, 100.00% of users gave Scopus BioPharma an outperform vote while only 61.00% of users gave Aridis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAridis PharmaceuticalsOutperform Votes12261.00% Underperform Votes7839.00% Scopus BioPharmaOutperform Votes2100.00% Underperform VotesNo Votes Do insiders and institutionals have more ownership in ARDS or SCPS? 9.7% of Aridis Pharmaceuticals shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher valuation & earnings, ARDS or SCPS? Scopus BioPharma has lower revenue, but higher earnings than Aridis Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAridis Pharmaceuticals$3.09M0.00-$30.37MN/AN/AScopus BioPharmaN/AN/A-$11.61MN/AN/A SummaryAridis Pharmaceuticals beats Scopus BioPharma on 5 of the 7 factors compared between the two stocks. Get Aridis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARDS vs. The Competition Export to ExcelMetricAridis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10,000.00$7.07B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E RatioN/A5.4725.4719.00Price / SalesN/A306.08447.5876.30Price / CashN/A65.6738.0134.83Price / BookN/A6.717.644.62Net Income-$30.37M$138.33M$3.18B$245.85M Aridis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARDSAridis PharmaceuticalsN/AN/AN/AN/A$10,000.00$3.09M0.0030SCPSScopus BioPharmaN/A$0.00flatN/A-91.7%$13,000.00N/A0.009VAXXVaxxinityN/A$0.00flatN/A-99.3%$13,000.00N/A0.0090High Trading VolumeEVLOEvelo BiosciencesN/A$0.00flatN/A-95.3%$9,000.00N/A0.00120Options VolumeNews CoverageCMRAComera Life SciencesN/A$0.00flatN/A-99.4%$6,000.00$630,000.000.002High Trading VolumeGNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastCALACalithera BiosciencesN/A$0.00flatN/A-97.0%$3,000.00N/A0.0060Analyst ForecastNews CoverageAMPEAmpio PharmaceuticalsN/A$0.00-79.0%N/A-99.9%$2,000.00N/A0.0020Analyst ForecastNews CoverageGap DownHigh Trading VolumeCLVRClever LeavesN/A$0.00-50.0%N/A-100.0%$2,000.00$17.42M0.00560Gap DownHigh Trading VolumeEFTReFFECTOR TherapeuticsN/A$0.00flat$24.00+11,999,900.0%-100.0%$1,000.00$3.55M0.0010PXMDPaxMedicaN/A$0.00-99.7%N/A-100.0%$1,000.00N/A0.002Gap Down Related Companies and Tools Related Companies SCPS Alternatives VAXX Alternatives EVLO Alternatives CMRA Alternatives GNCA Alternatives CALA Alternatives AMPE Alternatives CLVR Alternatives EFTR Alternatives PXMD Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARDS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredWarning: China Launches AI Attack on AmericaIf you have any money in AI stocks, pay attention because... According to Louis Navellier, the legendary in...InvestorPlace | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aridis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aridis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARDS Stock Alerts